GlassScriptPhysician profile
Jenny Uremovich
NPI 1861927188
$4,689.57
in general payments reported to CMS, 2019-2025
33 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.22 · 2021: $103 · 2022: $596 · 2023: $397 · 2024: $1,367 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,173.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,800.00 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $246.93 | 2021-2025 | |
| Organon LLC | $141.76 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $140.96 | 2023-2025 | Myfembree |
| Abbvie INC. | $133.66 | 2022-2023 | Lo Loestrin Fe, Liletta |
| Applied Medical Resources Corporation | $108.33 | 2022 | |
| Millicent US INC | $104.75 | 2023-2025 | Intrarosa, Femlyv, Femring |
| Pfizer INC. | $102.58 | 2022-2025 | |
| Shield Therapeutics INC | $95.56 | 2022-2024 | |
| Sage Therapeutics, LLC | $92.04 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $87.90 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $84.25 | 2023-2025 | Endosee, Summit Doppler |
| Hologic Sales and Service, LLC | $73.41 | 2023 | Acessa Provu System, Myosure Tissue Removal Device, Coolseal Generator |
| Bayer Healthcare Pharmaceuticals INC. | $64.24 | 2022-2025 | |
| Avion Pharmaceuticals | $49.48 | 2021-2023 | Balcoltra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.43 | 2023-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $38.30 | 2025 | Qelbree |
| Novo Nordisk INC | $32.50 | 2023-2025 | Wegovy, Saxenda |
| Daiichi Sankyo INC. | $25.11 | 2022 | |
| Octapharma USA, INC. | $23.37 | 2025 | Fibryga |
| Channel Medsystems, INC. | $21.50 | 2022 | |
| Becton, Dickinson and Company | $18.96 | 2023 | Bd Onclarity |
| Lundbeck LLC | $18.83 | 2022 | |
| Myovant Sciences INC. | $18.24 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.22 | 2019 | |
| Therapeuticsmd, INC. | $15.37 | 2022 | |
| Mission Pharmacal Company | $14.58 | 2022 | |
| Merck Sharp & Dohme LLC | $13.93 | 2022 | |
| Convatec INC. | $13.49 | 2022 | |
| Ascend Therapeutics US, LLC | $13.14 | 2024 | |
| Exact Sciences Corporation | $12.86 | 2023 | Cologuard Collection Kit |
| Acessa Health INC. | $12.48 | 2021 | |
| Medicem INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Uremovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.